jRCTs031240436招募中不适用
Study on the efficacy and safety of the omega 3 fatty acid for IFALD (ESFstudy)
未提供0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 15
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- No limit 至 20age old not（—）
- 性别
- All
入选标准
- •Patients who may develop IFALD or patients who have developed IFALD. Patients who may develop IFALD are defined as those meeting criteria (1) - (3) below: (1) A nutritional state dependent on parenteral nutrition (amino acids and lipid emulsion) for more than 2 weeks due to severe bowel dysfunction or significant intestinal loss (2) Difficulty in establishing enteral nutrition (3) Meeting either (a) or (b) below: (a) DB levels consistently >= 1 mg/dL in two measurements taken at least one week apart within 4 weeks before registration (b) Hepatobiliary enzyme level (any one of AST, ALT, or gamma GTP) consistently >= 2 times standard value of the facility in two measurements taken at least one week apart within 4 weeks before registration. Patients who have developed IFALD are defined as those meeting criteria (1) - (3) below: (1) A nutritional state dependent on parenteral nutrition (amino acids and lipid emulsion) for more than 2 weeks due to severe bowel dysfunction or significant intestinal loss (2) Difficulty in establishing enteral nutrition (3) DB levels consistently >= 2 mg/dL for more than 2 weeks
- •Age at enrollment must be less than 20-year-old
- •Patients must be eligible for a washout period of at least 28 days (14 days in cases of less than 1 year old) if they have used a fish oil emulsion (Omegaven or SMOFlipid) within 28 days before obtaining consent
- •Patients who can be hospitalized during Omegaven treatment
- •Written informed consent (>= 18-year-old)
- •~7-year-old: Written informed consent from the legal guardian surrogate of the patients 7~16-year-old: Written informed consent from the patient's legal guardian surrogate and explanation using an assent document for patients
- •16~18-year-old: Written informed consent from both of the patients themselves and the legal guardian surrogate of the patients and explanation using an assent document for patients
排除标准
- •Patients who are expected to be able to increase the amount of enteral nutrition gradually and to be able to terminate parenteral nutrition (both amino acids and lipid emulsions). For patients under 1-year-old, the amount of enteral nutrition is expected to reach 120 ml/kg/day and 100 kcal/kg/day. For patients over 1 year old, the amount of enteral nutrition does not reach the estimated energy requirement based on the dietary reference intake for Japanese (2020 Edition).
- •Patients with comorbidities that may cause cholestatic liver failure other than intestinal failure and parenteral nutrition (e.g., infection, biliary obstructive disease, hemorrhage, hemolytic jaundice) or patients suffering from or strongly suspected to have lipid metabolism abnormalities
- •Patients with irreversible severe hepatic dysfunction or failure who meet any of the following conditions
- •<Symptoms of portal hypertension>
- •(1)Untreatable thrombocytopenia (< 30000/mm3) or leukopenia (< 5000/mm3) associated with hypersplenism
- •(2)associated with varices
- •<Grade III or higher degree hepatic encephalopathy>
- •<untreatable coagulation abnormalities (PT INR >= 1.6)>
- •Patients who are scheduled for surgery not related to intestinal failure within 56 days of enrollment
- •Patients who have participated in other clinical trials or interventional studies within 28 days before obtaining consent
- •Patients with life-threatening respiratory failure, circulatory failure, shock, stroke, embolism, or undiagnosed coma
- •Contraindications as listed within the Appendix (U.S. version)
- •<Known hypersensitivity to fish or eggs or the active ingredient or excipients>
- •<Severe bleeding disorders due to potential effects on platelet aggregation>
- •<Hypertriglyceridemia (>= 1000 mg/dL) >
- •Pregnant or lactating patients
- •Other patients who the principal investigator deems inappropriate for this study
结局指标
主要结局
-
The ratio of patients who were able to prevent or improve IFALD to all examinees
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
EDEN studyCKD with DyslipidemiajRCTs05124026220
招募中
不适用
EBUS-Cryo studyLung CancerjRCTs03225008885
进行中（未招募）
不适用
Optimization of glycaemic control using a tablet-based insulin titrationalgorithm in hospitalized patients with type 2 diabetesDiabetes mellitus type 2MedDRA version: 16.0Level: PTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-001295-38-ATMedizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. für Endokrinologie und Stoffwechsel
进行中（未招募）
1 期
A Study to Find Out How Effective and Safe Different Treatments are in Patients Who Have a Type of Lung Cancer (Known as Non-Small Cell Lung Cancer [Stage III])on-Small Cell Lung Cancer (NSCLC)MedDRA version: 23.1Level: LLTClassification code 10084713Term: TumorSystem Organ Class: 100000004864EUCTR2021-004149-19-NOF. Hoffmann La Roche Ltd.320
进行中（未招募）
1 期
A Study to Find Out How Effective and Safe Different Treatments are in Patients Who Have a Type of Lung Cancer (Known as Non-Small Cell Lung Cancer [Stage III])on-Small Cell Lung Cancer (NSCLC)MedDRA version: 23.1Level: LLTClassification code 10084713Term: TumorSystem Organ Class: 100000004864EUCTR2021-004149-19-DEF. Hoffmann La Roche Ltd.220